Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2361]

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in...

Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )

SMMART Program: A multi-omics tumour board with a focus on breast cancer

Dr Ben Kong - Oregon Health & Science University, Portland, USA

SMMART Program: A multi-omics tumour board with a focus on breast cancer ( Dr Ben Kong - Oregon Health & Science University, Portland, USA )

PC14586: The first orally bioavailable small molecule reactivator of Y220C...

Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA

PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development ( Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA )

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in...

Prof Georgina Long - University of Sydney, Sydney, Australia

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma ( Prof Georgina Long - University of Sydney, Sydney, Australia )

Clinical validation of a targeted methylation-based multi-cancer early...

Dr Eric Klein - Cleveland Clinic, Cleveland, USA

Clinical validation of a targeted methylation-based multi-cancer early detection test ( Dr Eric Klein - Cleveland Clinic, Cleveland, USA )

First-line pembrolizumab plus chemotherapy for patients with advanced squamous...

Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General...

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 ( Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada )

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small...

Dr Erminia Massarelli - City of Hope, Duarte, USA

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer ( Dr Erminia Massarelli - City of Hope, Duarte, USA )

Incorporating KRAS as a novel biomarker: Challenges and opportunities

Prof Ales Ryska - Charles University, Prague, Czech Republic

Incorporating KRAS as a novel biomarker: Challenges and opportunities ( Prof Ales Ryska - Charles University, Prague, Czech Republic )

Real world data and diagnostics in patients with NSCLC with EGFR exon 20...

Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio...

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions ( Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro )

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC...

Prof Andrea Filippi - University of Pavia, Pavia, Italy

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for chemotherapy ( Prof Andrea Filippi - University of Pavia, Pavia, Italy )

Promise of personalised medicine for patients with prostate cancer

Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt...

Promise of personalised medicine for patients with prostate cancer ( Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt Attard )

More from ecancer